Epidemiologic and clinical implications of second-generation pneumococcal conjugate vaccines

Carmen Muñoz-Almagro; Adoracion Navarro-Torne; Roman Pallares

doi:10.1007/s11908-013-0326-4

Epidemiologic and clinical implications of second-generation pneumococcal conjugate vaccines

Curr Infect Dis Rep. 2013 Apr;15(2):184-90. doi: 10.1007/s11908-013-0326-4.

Authors

Carmen Muñoz-Almagro¹, Adoracion Navarro-Torne, Roman Pallares

Affiliation

¹ Molecular Microbiology Department, University Hospital Sant Joan de Déu, Passeig Sant Joan de Déu, Esplugues, 08950, Barcelona, Spain, cma@hsjdbcn.org.

PMID: 23381547
DOI: 10.1007/s11908-013-0326-4

Abstract

This review is based on published literature about some of the potential advantages and challenges of the second generation of pneumococcal conjugate vaccines, with special reference to 13-valent vaccine in children and adults.